Johnson & Johnson won U.S. approval on April 30, 2025, of its new drug Imaavy for generalized myasthenia gravis. This story was originally published on BioPharma Dive. To receive daily news and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback